Wave Life Sciences, Inc. WVE
We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid ("RNA") medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our pipeline is focused on our obesity (WVE-007), alpha-1 antitrypsin deficiency ("AATD") (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs for Duchenne muscular dystrophy ("DMD") and Huntington's disease ("HD"), as well as several preclinical programs utilizing our versatile RNA medicines platform.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M | $20.1M | $16.0M | $14.4M | $3.9M | $1.1M |
| R&D | $182.8M | $159.7M | $130.0M | $115.9M | $121.9M | $130.9M | $175.4M | $134.4M | $79.3M | $40.8M |
| SG&A | $75.3M | $59.0M | $51.3M | $50.5M | $46.1M | $42.5M | $48.9M | $39.5M | $27.0M | $16.0M |
| Total operating expenses | $258.1M | $218.7M | $181.3M | $166.4M | $168.0M | $173.5M | $224.3M | $173.9M | $106.3M | $56.8M |
| Operating income | -$215.4M | -$110.4M | -$68.0M | -$162.7M | -$127.0M | -$153.4M | -$208.3M | -$159.5M | -$102.4M | -$55.7M |
| Pre-tax income | -$204.4M | -$97.0M | -$58.2M | -$161.1M | -$122.4M | -$150.8M | -$193.6M | -$146.6M | -$101.1M | -$55.2M |
| Income tax | $0 | $0 | $677.0K | $681.0K | $204.0K | $841.0K | $0 | $69.0K | $842.0K | $482.0K |
| Net income | -$204.4M | -$97.0M | -$57.5M | -$161.8M | -$122.2M | -$149.9M | -$193.6M | -$146.7M | -$102.0M | -$55.7M |
| EPS, basic | -1.21 | -0.70 | -0.54 | -2.05 | -2.36 | — | — | — | — | — |
| EPS, diluted | -1.21 | -0.70 | -0.54 | -2.05 | -2.36 | -3.82 | -5.72 | -5.06 | -3.85 | -2.44 |
| Shares, diluted (wtd. avg.) | $168.6M | $138.3M | $106.1M | $78.9M | $51.8M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $602.1M | $302.1M | $200.4M | $88.5M | $150.6M | $184.5M | $147.2M | $174.8M | $142.5M | $150.3M |
| Receivables | $1.3M | $1.4M | $21.1M | — | — | $30.0M | $20.0M | $10.0M | $1.0M | — |
| Total current assets | $614.8M | $320.4M | $235.4M | $98.5M | $162.6M | $230.0M | $185.5M | $202.3M | $150.5M | $152.0M |
| Property, plant and equipment | $7.4M | $10.1M | $13.1M | $17.3M | $22.3M | $29.2M | $36.4M | $39.9M | $27.3M | $8.6M |
| Total assets | $638.5M | $352.2M | $274.9M | $146.4M | $207.0M | $279.2M | $284.2M | $295.9M | $181.8M | $164.8M |
| Accounts payable | $15.7M | $16.3M | $12.8M | $16.9M | $7.3M | $13.8M | $9.1M | $13.1M | $7.6M | $4.9M |
| Total current liabilities | $95.1M | $111.0M | $186.4M | $71.5M | $64.2M | $121.0M | $118.2M | $130.0M | $18.2M | $12.2M |
| Total liabilities | $112.3M | $134.8M | $227.4M | $183.6M | $166.6M | $188.6M | $212.6M | $214.7M | $34.4M | $22.1M |
| Retained earnings | -$1.33B | -$1.12B | -$1.02B | -$967.3M | -$805.5M | -$683.3M | -$533.4M | -$339.7M | -$192.7M | -$90.5M |
| Total equity | $518.4M | $209.5M | $39.6M | -$45.1M | $32.5M | $82.8M | $63.7M | $73.3M | $139.6M | $134.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$187.5M | -$151.0M | -$19.4M | -$127.8M | -$89.0M | -$116.0M | -$188.2M | -$22.9M | -$83.7M | -$31.9M |
| Depreciation and amortisation | $3.4M | $3.9M | $5.0M | $6.6M | $7.5M | $8.1M | $7.6M | $5.6M | $2.2M | $784.0K |
| Capital expenditure | $718.0K | $938.0K | $1.1M | $1.4M | $560.0K | $1.3M | $3.9M | $9.9M | $18.9M | $5.6M |
| Investing cash flow | -$718.0K | -$938.0K | -$1.1M | -$1.3M | -$560.0K | -$1.3M | -$3.9M | -$9.9M | -$18.9M | -$5.6M |
| Financing cash flow | $488.2M | $253.9M | $132.5M | $67.2M | $55.8M | $154.5M | $164.4M | $65.1M | $94.4M | $29.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197330.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |